ArticleJournal of cancer research and clinical oncology2022

PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.

Yixiang Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.